The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.
about
Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosusProgress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activitySerum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodiesAutologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry.EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres.Cytokine profile in childhood-onset systemic lupus erythematosus: a cross-sectional and longitudinal study.Relationship between Serum Level of Interleukin-2 in Patients with Systemic Lupus Erythematosus and Disease Activity in Comparison with Control Group.Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk.Which outcome measures in SLE clinical trials best reflect medical judgment?Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trialPreferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expressionBiokinetic Mechanisms Linked With Musculoskeletal Health Disparities: Stochastic Models Applying Tikhonov's Theorem to Biomolecule HomeostasisSerum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus.Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus.Perceptions of racism in healthcare among patients with systemic lupus erythematosus: a cross-sectional study.Characteristics of azathioprine use and cessation in a longitudinal lupus cohort.Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort studyThe BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally.Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control.Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus.Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic Lupus erythematosus.Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study.Independent association of glucocorticoids with damage accrual in SLE.Non-pathogenic tissue-resident CD8+ T cells uniquely accumulate in the brains of lupus-prone mice.Ultrasound detects subclinical joint inflammation in the hands and wrists of patients with systemic lupus erythematosus without musculoskeletal symptoms.IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.Obesity and cytokines in childhood-onset systemic lupus erythematosus.Measuring outcomes in systemic lupus erythematosus clinical trials.Top 10 things to know about lupus activity measures.Assessment of condyle, masseter and temporal muscles volumes in patients with juvenile systemic lupus erythematosus: A cross-sectional study.The validity and reliability of Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) in a Turkish population.Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.Comparison of estimates of body fat content in childhood-onset systemic lupus erythematosus.International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies.Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis.Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.Reduction of Cerebral and Corpus Callosum Volumes in Childhood-Onset Systemic Lupus Erythematosus: A Volumetric Magnetic Resonance Imaging Analysis.Extremely hypotrophic newborn of mother with systemic lupus erythematosus and antiphospholipid syndrome.Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus.Meaningful patient engagement in inflammatory arthritis: development of the Patient Motivation Questionnaire.
P2860
Q26822662-D573E43E-A815-404F-BA68-BDDD49FC75D9Q28079267-734E1C5C-740B-475F-BD64-2778CE7496B7Q28268159-A0AC7674-401A-407F-86D0-6CD01D85CA6EQ30582614-935CFC97-E0B4-47A9-A0FB-97E9939F98BBQ30886868-1792B028-7D15-43EF-A178-3F2E403CE80DQ33653385-31B889DA-5D6A-4F85-895C-3CC46B43DF50Q34108426-68691C07-82EE-47FD-A5AF-F39C09D93157Q34409903-81470EFF-5BD4-4C09-B2B2-20CFAD30E4F9Q34478866-C431AC37-B0FA-41AC-ADD1-E85AC637232EQ34512800-75C026EA-2BDA-41A0-8821-4AE36F61BD7CQ35018126-86A1AF9B-0C3C-48BB-913B-069D2CF91518Q35091185-75D9EE95-213B-49FA-B58A-C5C3B2FE9BFEQ35666611-95251400-B946-4396-9C5C-C4D639F07C14Q35743904-F8B9C22D-5E6F-46A8-BB59-A15262D93343Q35992226-932EF8C4-4434-4EE9-99DA-72BB07A5D37EQ35992235-75423CD8-51A0-40D8-B35A-839E955C425CQ36321563-24A4C245-3D7B-4ED6-B523-DDB882EB8801Q36331877-71E41C2C-8052-42D2-ACDE-C480680E0695Q36409293-1D6BEF0F-5E56-42EB-8E08-135664FC37DAQ36433143-3359297B-82AE-4276-A244-B7136067FE0DQ36608536-B454EBFA-BF49-4F5F-AEEB-C1000145C188Q36869519-2B36F99D-B3C7-4C9A-B042-2A1222F909CDQ37464030-0BEDCE54-F0BA-4C29-B513-907E3B4AD2D0Q37591123-A4E23FDA-A841-4920-A659-57FBDD0B5EE3Q37598913-065EDFD9-07F1-4CFE-80F4-05419177D0B0Q37679294-E8DA4BCE-FEE8-4CD1-AB57-312928A512F3Q37704576-DD6785B5-956F-40C9-954E-4E6A0AB583E2Q37914899-52CAE9E3-CD94-47E9-8791-395C597CA12DQ38100735-80FBE405-9662-4D1C-9634-9622E7CB4658Q38679869-473EA0CD-95DB-4543-A4EF-E603D211AA05Q38807178-322D9BC2-B14B-47EC-BB32-1A8041EC9B76Q39095546-EAD5C15B-B05A-41D9-9F1C-D021959A0251Q39166359-051FD9A6-6432-435A-B5D9-1EBBB6B24B80Q39716610-4D0DD7CA-E903-40C2-AC73-1A6D2A405AA2Q40432262-00DA535E-B368-4694-8076-651FE861806BQ40750370-7E2C540D-FA54-482A-B045-BD5FD747DD1EQ40845375-831C8360-6857-4E67-A9DE-6265592B9294Q41930959-C180BFF8-FD4E-48F2-81FE-55A4F92373EBQ46160179-6AC586C6-98AB-4685-80F9-0547D384D051Q46885930-0A51A50E-C947-45C5-9400-55C9BF77BB17
P2860
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@ast
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@en
type
label
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@ast
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@en
prefLabel
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@ast
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@en
P2093
P2860
P50
P356
P1433
P1476
The use of Systemic Lupus Eryt ...... lupus erythematosus patients.
@en
P2093
Anisur Rahman
Athiveeraramapandian Prabu
Bridget Griffiths
Chee-Seng Yee
Christopher Edwards
David D'Cruz
Lee-Suan Teh
Mohammed Akil
Neil McHugh
Yasmeen Ahmad
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEQ376
P577
2011-01-18T00:00:00Z